eicosapentaenoic acid ethyl ester has been researched along with Huntington Disease in 8 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
Excerpt | Relevance | Reference |
---|---|---|
"To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, improves the motor features of Huntington disease." | 9.13 | Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. ( , 2008) |
"To determine whether ethyl-eicosapentaenoic acid (ethyl-EPA), an omega-3 fatty acid, improves the motor features of Huntington disease." | 5.13 | Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. ( , 2008) |
"The Unified Huntington's Disease Rating Scale (UHDRS) was used for assessment." | 2.71 | Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. ( Greenamyre, JT; Hayden, MR; Hersch, S; Horrobin, DF; Leavitt, BR; Manku, M; Murck, H; Puri, BK; Rosenblatt, A; Ross, CA; Sword, A; Vaddadi, KS, 2005) |
"Cystamine treatment of various genetic models of HD demonstrated protection against neurodegeneration and/or improvement in behavior." | 1.37 | Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. ( Leavitt, BR; Sivananthan, SN, 2011) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Morsy, S | 1 |
Khalil, SM | 1 |
Doheim, MF | 1 |
Kamel, MG | 1 |
El-Basiony, DSM | 1 |
Ahmed Hassan, HI | 1 |
Eisa, AA | 1 |
Anh Ngoc, CT | 1 |
Dang, NP | 1 |
Hirayama, K | 1 |
Huy, NT | 1 |
Ferreira, JJ | 1 |
Rosser, A | 1 |
Craufurd, D | 1 |
Squitieri, F | 1 |
Mallard, N | 1 |
Landwehrmeyer, B | 1 |
Sivananthan, SN | 1 |
Leavitt, BR | 3 |
Puri, BK | 2 |
Hayden, MR | 2 |
Ross, CA | 1 |
Rosenblatt, A | 1 |
Greenamyre, JT | 1 |
Hersch, S | 1 |
Vaddadi, KS | 2 |
Sword, A | 1 |
Horrobin, DF | 2 |
Manku, M | 2 |
Murck, H | 2 |
Van Raamsdonk, JM | 1 |
Pearson, J | 1 |
Rogers, DA | 1 |
Lu, G | 1 |
Barakauskas, VE | 1 |
Barr, AM | 1 |
Honer, WG | 1 |
Bydder, GM | 1 |
Counsell, SJ | 1 |
Corridan, BJ | 1 |
Richardson, AJ | 1 |
Hajnal, JV | 1 |
Appel, C | 1 |
Mckee, HM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's Disease[NCT00146211] | Phase 3 | 300 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
Coenzyme Q10 in Huntington's Disease (HD)[NCT00608881] | Phase 3 | 609 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Futility analysis failed to showed likelihoo of benefit of CoQ 2400 mg/day.) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. A total score was calculated by summing up all the individual behavioral frequency items (range 0-56) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 1.39 |
B - Placebo | 1.43 |
The Unified Huntington's Disease Rating Scale (UHDRS) behavioral subscale assesses frequency and severity of psychiatric-related symptoms, including depressed mood, apathy, low self-esteem/guilt, suicidal thoughts, anxiety, irritable behavior, aggressive behavior, obsessional thinking, compulsive behavior, delusions, and hallucinations. The total score is the sum of the product of the individual behavioral frequency and severity items (range 0-176) with higher scores representing more severe behavioral impairment. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 4.29 |
B - Placebo | 5.06 |
"The functional assessment checklist includes 25 questions about common daily tasks. A score of 1 is given for each yes reply and a score of 0 is given for each no reply (scale range is 0-25). Higher scores indicate better functioning." (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.93 |
B - Placebo | -8.02 |
The independence scale assesses independence on a 0 to 100 scale with higher scores indicating better functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -26.30 |
B - Placebo | -24.86 |
Stroop Interference Test - color naming score is the total number of correct colors identified in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -14.21 |
B - Placebo | -14.51 |
Stroop Interference Test - interference score is the total number of correct items identified in 45 seconds and reflects an executive measure of inhibitory ability. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -7.57 |
B - Placebo | -8.61 |
Stroop Interference Test - word reading score is the total number of correct words read in 45 seconds and reflects processing speed. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -15.25 |
B - Placebo | -19.13 |
The SDMT assesses attention, visuoperceptual processing, working memory, and cognitive/psychomotor speed. The score is the number of correctly paired abstract symbols and specific numbers in 90 seconds with higher scores indicating better cognitive functioning. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -10.95 |
B - Placebo | -11.36 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -4.53 |
B - Placebo | -4.76 |
The motor section of the Unified Huntington's Disease Rating Scale (UHDRS) assesses motor features of Huntington disease with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural stability. The total motor score is the sum of all the individual motor ratings, with higher scores (124) indicating more severe motor impairment than lower scores. The score ranges from 0 to 124. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 18.06 |
B - Placebo | 19.18 |
The verbal fluency test is typically considered a measure of executive function. The score is the number of correct words produced across three 1-minute trials. (NCT00608881)
Timeframe: Baseline and Month 60
Intervention | units on a scale (Least Squares Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | -5.07 |
B - Placebo | -4.47 |
The primary outcome variable at the start of the trial was the change in TFC score from baseline to Month 60. The Data and Safety Monitoring Board recommended to the trial leadership that they reconsider how they accommodate missing data from subjects who die in their primary analysis of the change in TFC score. Based on these recommendations, the trial leadership changed the primary analysis to that of a joint rank approach. TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | rank (Mean) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 303.3 |
B - Placebo | 306.7 |
(NCT00608881)
Timeframe: 5 years
Intervention | participants completing study on drug (Number) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 98 |
B - Placebo | 108 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 917 |
B - Placebo | 911 |
TFC consists of five ordinally scaled items assessing a person's capacity with: (1) occupation; (2) financial affairs; (3) domestic responsibilities; (4) activities of daily living; and (5) independent living. Total score ranges from zero (worst) to 13 (best). (NCT00608881)
Timeframe: 5 years
Intervention | days to event (Median) |
---|---|
A - Coenzyme Q10 2400 mg/Day | 553 |
B - Placebo | 549 |
2 reviews available for eicosapentaenoic acid ethyl ester and Huntington Disease
Article | Year |
---|---|
Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis.
Topics: Eicosapentaenoic Acid; Humans; Huntington Disease; Randomized Controlled Trials as Topic; Treatment | 2019 |
Ethyl-EPA in Huntington disease: potentially relevant mechanism of action.
Topics: Animals; Brain; Clinical Trials as Topic; Eicosapentaenoic Acid; Humans; Huntington Disease | 2007 |
4 trials available for eicosapentaenoic acid ethyl ester and Huntington Disease
Article | Year |
---|---|
Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Topics: Adult; Aged; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Huntington Disease; Male; M | 2015 |
Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
Topics: Adult; Analysis of Variance; Canada; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up S | 2008 |
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Apoptosis; Brain; Cohort Studies; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; | 2005 |
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment.
Topics: Aged; Atrophy; Brain; Double-Blind Method; Dyskinesia, Drug-Induced; Eicosapentaenoic Acid; Female; | 2002 |
2 other studies available for eicosapentaenoic acid ethyl ester and Huntington Disease
Article | Year |
---|---|
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disea | 2011 |
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
Topics: Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphopr | 2005 |